Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials
Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 mil... Series B funding will accelerate development of new AI disease models for lung and heart conditions, while expanding the company's imaging analytics platform. Biotech Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials Series B funding will accelerate development of new AI disease models for lung and heart conditions, while expanding the company's imaging analytics platform.
Key Takeaways
- Cate Lawrence 1 hour ago Share Share Send email Copy link Qureight , an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures .
Existing investors Hargreave Hale AIM VCT , XTX Ventures, Guinness Ventures , Meltwind, and Ascension also participated in the round.
- The Qureight platform includes: Global imaging CRO services to improve image handling in clinical trials and support rapid site onboarding and patient inclusion decisions.
Proprietary AI Lung image biomarkers enable the quantification of compartment-specific structural changes that indicate disease progression in a clinical trial.
- Qureight's services are already being utilised by biopharma partners, providing real-time insights and precision endpoints to accelerate clinical trials in a number of fibrotic lung diseases.
According to Dr Muhunthan Thillai, MD, PhD, Co-founder and CEO, Qureight: "We are excited to bring on Molten Ventures to lead this new financing round and for Dr Inga Deakin to join our Board of Directors.
- " He also notes that expanding the company's 3D imaging deep learning models with its new AI laboratory will complement our existing dominance in lung fibrosis, allow it to enter new markets, and solidify its leadership position in the lung and heart imaging CRO market.
" Dr Inga Deakin PhD, Partner, Molten Ventures, added: "Qureight demonstrates how AI, powered by real-world data, can accelerate discovery and transform clinical research.
- What would you like us to deliver to you?
Stats & Key Facts
- #Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 mil...
- #Biotech Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials Series B funding will accelerate development of new AI disease models for lung and heart conditions, while expanding the company's imaging analytics platform.
- #Cate Lawrence 1 hour ago Share Share Send email Copy link Qureight , an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures .
- #This brings the company's funding to over €27 million.
Series B funding will accelerate development of new AI disease models for lung and heart conditions, while expanding the company's imaging analytics platform. Biotech Qureight secures $20M Series B to expand AI-powered imaging platform for clinical trials Series B funding will accelerate development of new AI disease models for lung and heart conditions, while expanding the company's imaging analytics platform. Cate Lawrence 1 hour ago Share Share Send email Copy link Qureight , an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has raised $20 million in a Series B financing, led by Molten Ventures .
Existing investors Hargreave Hale AIM VCT , XTX Ventures, Guinness Ventures , Meltwind, and Ascension also participated in the round. This brings the company's funding to over €27 million. The company is building an AI imaging laboratory to house Qureight's 3D chest imaging Foundation Model, significantly reducing both the data requirement and the time needed to develop new disease models.
The Qureight platform includes: Global imaging CRO services to improve image handling in clinical trials and support rapid site onboarding and patient inclusion decisions. Proprietary AI Lung image biomarkers enable the quantification of compartment-specific structural changes that indicate disease progression in a clinical trial. Data science products, including synthetic control arms that enable comparisons to real trial arms, reducing study costs and duration.
For more details please read the original article at Tech.eu.
Continue Learning
Comments
Sign in to join the conversation